Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2021.07.015 http://scihub22266oqcxt.onion/10.1016/j.ijid.2021.07.015 34273512!8278827!34273512     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34273512&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2021 ; 109 (ä): 261-268 Nephropedia Template TP {{tp|p=34273512|t=2021. Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19 |pdf=|usr=}}{{34273512}} gab.com Text Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19 JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34273512 #FOAvip BACKGROUND: The effects of high-intensity immunity on coronavirus disease 2019 (COVID-19) remain unclear. Antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are preferentially induced in inpatients with COVID-19 compared with outpatients with milder disease, and immunosuppression is the standard therapy for severe cases. This study investigated the relationship between cross-reactive antibody production against seasonal human coronavirus and the clinical course of COVID-19. METHODS: Among the immunogenic epitopes of SARS-CoV-2, conserved peptides in human coronavirus OC43 were searched and synthesized. Enzyme-linked immunosorbent assay was designed to detect antibodies against synthesized peptides. Antibody titres against S2' cleavage site epitopes near fusion peptides of SARS-CoV-2 and OC43 were determined in the sera of 126 inpatients with COVID-19. The correlation between antibody titres and clinical data was analysed. RESULTS: Inpatients with COVID-19 who produced antibodies against OC43 did not develop severe or fatal pneumonia. Antibody titres against the corresponding epitope of SARS-CoV-2 did not differ between inpatients with severe and mild COVID-19. Antibody titres against the OC43 epitope increased more than those against SARS-CoV-2 during the first 2 weeks of COVID-19. CONCLUSIONS: Immunity to seasonal human coronavirus OC43 effectively enhanced recovery from COVID-19. Detecting cross-reactive antibodies to OC43 may help to predict prognosis for patients with COVID-19. Twit Text FOAVip Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19 ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34273512 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34273512 #FOAvip English Wikipedia <ref>{{Cite pmid|34273512}}</ref> Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19 #MMPMID34273512 Yamaguchi T; Shinagawa T; Kobata H; Nakagawa H Int J Infect Dis 2021[Aug]; 109 (ä): 261-268 PMID34273512show ga BACKGROUND: The effects of high-intensity immunity on coronavirus disease 2019 (COVID-19) remain unclear. Antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are preferentially induced in inpatients with COVID-19 compared with outpatients with milder disease, and immunosuppression is the standard therapy for severe cases. This study investigated the relationship between cross-reactive antibody production against seasonal human coronavirus and the clinical course of COVID-19. METHODS: Among the immunogenic epitopes of SARS-CoV-2, conserved peptides in human coronavirus OC43 were searched and synthesized. Enzyme-linked immunosorbent assay was designed to detect antibodies against synthesized peptides. Antibody titres against S2' cleavage site epitopes near fusion peptides of SARS-CoV-2 and OC43 were determined in the sera of 126 inpatients with COVID-19. The correlation between antibody titres and clinical data was analysed. RESULTS: Inpatients with COVID-19 who produced antibodies against OC43 did not develop severe or fatal pneumonia. Antibody titres against the corresponding epitope of SARS-CoV-2 did not differ between inpatients with severe and mild COVID-19. Antibody titres against the OC43 epitope increased more than those against SARS-CoV-2 during the first 2 weeks of COVID-19. CONCLUSIONS: Immunity to seasonal human coronavirus OC43 effectively enhanced recovery from COVID-19. Detecting cross-reactive antibodies to OC43 may help to predict prognosis for patients with COVID-19. |*COVID-19[MESH] |*Coronavirus OC43, Human[MESH] |Antibodies, Viral[MESH] |Cross Reactions[MESH] |Humans[MESH] |SARS-CoV-2[MESH] |Seasons[MESH]Immunity against seasonal human coronavirus OC43 mitigates fatal deter(epmc).pdf DeepDyve Pubget Overpricing